Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Serious adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
1 finding from 1 review
Adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events up to week 12 · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).
1 finding from 1 review
Failure to induce remission at 6 weeks · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 6 weeks compared with placebo (high certainty).
2 findings from 1 review
Major bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life · patients with active cancer with venous thromboembolism
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
It is very uncertain whether probiotics changes any diarrhoea compared with other active treatment (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade ≥ 3 diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
Probiotics may leads to lower severity of diarrhoea: grade 3 or higher compared with other active treatment (low certainty).
1 finding from 1 review
Time to rescue medication ‐ not measured · participants with cancer treated with radiotherapy (with or without chemotherapy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Requiring rescue medication for diarrhoea · participants with cancer treated with radiotherapy (with or without chemotherapy)
It is very uncertain whether probiotics changes requiring rescue medication for diarrhoea compared with other active treatment (very low certainty).
1 finding from 1 review
Adverse events · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
All‐cause mortality · participants with cancer treated with radiotherapy (with or without chemotherapy)
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in induction of clinical remission CDAI < 150 compared with placebo (low certainty).
1 finding from 1 review